



## The adequacy of anticoagulation practice in a teaching hospital

Sarah M AlSharif<sup>1</sup>, Mohamad H Qari<sup>2</sup>, Weaam M Alrefai<sup>3</sup>, Afnan M Alhawi<sup>4</sup>, Sumaya J Khaldi<sup>5</sup>,  
Maria S AbuHadi<sup>6</sup>, Rawan A Almohammadi<sup>7</sup>

<sup>1, 3-7</sup> College of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia

<sup>2</sup> Consultant & Professor of hematology at the hematological department in King Abdul Aziz University, Jeddah, Saudi Arabia

### Abstract

**Background:** Venous thromboembolism (VTE) is a major problem in all hospitalized patients, which can be prevented by following practice guidelines. Appropriate identification and management of patients at risk is critical in order to maintain patient safety.

**Aim:** To determine the risk of VTE and the use of anticoagulant prophylaxis according to Caprini score for hospitalized patients at King Abdulaziz University Hospital (KAUH).

**Methodology:** We conducted a cross-sectional study at KAUH from July to August 2017. All inpatients from medical ward (aged  $\geq 40$  years), surgical ward (aged  $\geq 18$  years), and obstetrics and gynecology (OB/GYN) ward were included. Patients receiving anticoagulant treatment were excluded. We used the Caprini scoring system to assess the risk of VTE and recommended regimen.

**Results:** A total of 496 inpatients were included in the study. Of those patients, 33.3% were surgical, 31% were medical, and 35.7% were OB/GYN patients. The mean participant age was 48.62 years. The percentages of patients within the risk categories (low, moderate, high, and highest) were 7.5%, 9.7%, 25.2%, and 57.7%, respectively. Among our sample, 248 (50%) patients received VTE prophylaxis. However, 213 (42.9%) received appropriate pharmacological doses. Of the 248 (50%) patients who did not receive any prophylaxis, 5.8% were in the low-risk group, 10.1% had contraindications, while the majority (34.1%) had no obvious reason.

**Conclusion:** The majority of the patients who were eligible for prophylaxis were managed properly. But still, there is underuse of prophylaxis in the sample as whole. Also, the implementation of mechanical prophylaxis is needed in our hospital.

**Keywords:** VTE prophylaxis, Caprini score, anticoagulants, risk assessment

### Introduction

Venous thromboembolism (VTE) consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), which can be a complication of DVT if not detected early [1]. It has been occurring in high rates in adult populations, with an incidence of 1 per 1000 annually, specifically slightly more in men than women [2]. In Saudi Arabia, roughly 25,000 people develop VTE annually [3]. Venous thromboembolism is a serious issue that has high mortality and morbidity rates in hospitalized patients [4]. Patients with VTE have an increased risk for complications such as post-thrombotic syndrome, pulmonary hypertension, and recurrence of thrombosis; and about 10% of hospitalized patients die from PE [5, 6]. Despite strong evidence supporting the benefit of VTE prophylaxis in reducing the risk, it is still inadequately used in at-risk patients according to several studies [5, 7]. The first step in providing appropriate VTE prophylaxis is to determine the patients who are at risk. As a consequence, several scores and models were designed to assess patient risk of venous thromboembolism. In this study we used the Caprini risk assessment model [4], which is an effective way to assess the risk of VTE by classifying patients into 4 categories: low, moderate, high, and highest risk [8]. Our aim in this study was to determine patients at risk for VTE and evaluate the use of anticoagulant prophylaxis according to Caprini score in King Abdulaziz University Hospital patients.

### Materials and Methods

#### Procedures

After gaining approval by the Institutional Review Board (IRB) of King Abdulaziz University, we conducted this cross-sectional study at KAUH, Jeddah, Saudi Arabia. Data were obtained from enrolled surgical and OB/GYN inpatients aged 18-years old and above, as well as medical inpatients aged 40 years and above during the period between July and August of 2017.

#### Data Collection

Patient data were obtained from the Phoenix System of KAUH. A Google form and Excel file were designed to collect the needed information which included patient identification (ID) number, demographics, body mass index, admission diagnosis, active diseases, current anticoagulant use (name, dose, route, duration), any other VTE prophylaxis, and Caprini score assessment; which is a computer-generated, retrospective, risk-scoring method validated in 2005. Table one shows the scoring system [5].

#### Statistical Analysis

Statistical analysis was performed using SPSS software, version 25. A qualitative analysis was conducted on all parts of the data. A crosstabs table was made showing the patients'

risk levels and administration of VTE prophylaxis. The appropriate doses were also assessed, and a chi-square test was used with a  $p$  value  $< .05$  being significant.

**Results**

During the period of the study (two months), 507 hospitalized patients who met the inclusion criteria were enrolled, 11 were excluded who were already taking warfarin prior to admission, resulting in a total of 496 inpatients. Among the total sample, 337 (67.9%) were women, and 159 (32.1%) were men. According to ward distribution, 33.3% were from the surgical ward, 31% were medical patients, and 35.7% were from the OB/GYN ward. The mean participant age was 48.62 years (min=18 years, max=102 years). The numbers of patients in each risk category (low, moderate, high, and highest) were 7.5%, 9.7%, 25.2%, and 57.7%, respectively. The mean Caprini-risk score was 5.60. Details of risk levels for each ward are shown in Table 2. Among the total sample, 248 (50%) patients received VTE prophylaxis; 213 of them (42.9%) were given the appropriate pharmacological doses [low-risk group 0%, moderate 0.8%, high 9.5%, highest 32.7%, ( $p = .000$ )]. Furthermore, 35 (7.1%) patients were

either given wrong doses or were at low risk for VTE, more details are shown in Table 3. On the other hand, 248 (50%) patients did not receive any prophylaxis; the majority (34.1%) had no obvious reason, 10.1% had contraindications, while 5.8% were in the low-risk group. Inappropriate anticoagulant dose administration was found highest in the medical ward (11%), followed by the surgical ward (6.1), then the OB/GYN ward (4.5%).

**Table 1:** (Caprini Risk Score System) <sup>[5]</sup>


| Risk Category | Caprini Score |
|---------------|---------------|
| Low           | 0-1           |
| Moderate      | 2             |
| High          | 3-4           |
| Highest       | 5 and above   |

**Table 2:** Caprini score levels according to ward

| Caprini Score Level | Wards         |                |              |
|---------------------|---------------|----------------|--------------|
|                     | Medical n=154 | Surgical n=165 | OB/GYN n=177 |
| Low                 | 5 (1%)        | 14 (2.8%)      | 18 (3.6%)    |
| Moderate            | 6 (1.2%)      | 9 (1.8%)       | 33 (6.7%)    |
| High                | 25 (5%)       | 37 (7.5%)      | 63 (12.7%)   |
| Highest             | 118 (23.8%)   | 105 (21.2%)    | 63 (12.7%)   |

**Table 3:** Distribution of patients receiving anticoagulant prophylaxis according to ward, risk level, and dosage

| Ward                             | Risk     | Appropriate |             |
|----------------------------------|----------|-------------|-------------|
|                                  |          | YES         | NO          |
| Medical:                         | Low      | 0           | 3 (2.5%)    |
|                                  | Moderate | 3 (2.5%)    | 2 (1.7%)    |
|                                  | High     | 13 (10.8%)  | 3 (2.5%)    |
|                                  | Highest  | 87 (72.5%)  | 9 (7.5%)    |
| Surgical:                        | Low      | 0           | 3 (3.9%)    |
|                                  | Moderate | 0           | 1 (1.3%)    |
|                                  | High     | 16 (21.1%)  | 1 (1.3%)    |
|                                  | Highest  | 50 (65.8%)  | 5 (6.6%)    |
| OB/GYN:                          | Low      | 0           | 2 (3.8%)    |
|                                  | Moderate | 1 (1.9%)    | 2 (3.8%)    |
|                                  | High     | 18 (34.6%)  | 1 (1.9%)    |
|                                  | Highest  | 25 (48.1%)  | 3 (5.8%)    |
| Total:<br>248 patients<br>(100%) | Low      | 0           | 8 (3.2%)    |
|                                  | Moderate | 4 (1.6%)    | 5 (2%)      |
|                                  | High     | 47 (19%)    | 5 (2%)      |
|                                  | Highest  | 162 (65.3%) | 17 (6.9%)   |
|                                  |          |             | 213 (85.9%) |



**Fig 1:** Contraindications to Anticoagulation, n = 219 NOR: no obvious reason, NSAIDs: Nonsteroidal anti-inflammatory drugs

## Discussion

In this observational, cross-sectional study, our goal was to identify patients at risk for VTE and evaluate whether they received appropriate thromboprophylaxis at KAUH. After collecting the data, it was understandable why more than half of the patients were women (67.9%) as our study included patients from the OB/GYN ward. Analysis revealed that most of the patients were at risk for VTE, with the majority falling into the highest-risk category (57.7%); while the high, moderate, and low-risk categories had the percentages of 25.2%, 9.7%, and 7.5%, respectively.

The reason the majority of our study participants fell into the highest-risk category (57.7%) could be the multifarious frequencies of VTE risk factors, participant age ( $M = 48.62$ ), as we had excluded medical patients below 40-years of age, as well as the fact that KAUH is a tertiary care center. In contrast, a study conducted in Jordan using the American College of Chest Physicians' (ACCP) guidelines showed that the majority of their sample fell in the low-risk category with no further explanation<sup>[9]</sup>.

From 507 patients, we excluded 11 patients who were taking warfarin, which is a treatment in itself and conflicts with the prophylactic use of anticoagulants. Among 496 inpatients, we found that 248 (50%) received VTE prophylaxis, and that 213 (42.9%) received the appropriate prophylactic doses. As we had expected, the rate of our hospital's agreement with the guidelines was statistically significant ( $p = .000$ ). This outcome is supported by another study conducted in Lebanon which concluded that teaching hospitals were compliant with VTE prophylaxis guidelines more than non-teaching hospitals<sup>[10]</sup>. The remaining 35 patients (7.1%) were either receiving wrong doses [moderate-risk group (1%), high-risk group (1%), and highest-risk group (3.4%)], or were administered VTE prophylaxis when they did not need it; low-risk patients (1.6%). Although, a study from India was recommending giving low-risk patients pharmacological and mechanical prophylaxis because they are still considered at risk for VTE<sup>[11]</sup>.

In this study, we found that pharmacological anticoagulation was superior to the use of mechanical prophylaxis. In our sample, 43.8% had contraindications to pharmacological anticoagulation, and only 2 patients received mechanical prophylaxis. In opposition to the study by Cohen *et al.*, where mechanical prophylaxis was used effectively in patients with contraindications<sup>[7]</sup>. A study by Asano *et al.* displayed the efficacy of mechanical prophylaxis by dividing the patients into two groups (control group, and treatment group using foot sole pump), the incidence of PE was lowered with ( $p < .008$ )<sup>[12]</sup>.

On the other hand, 248 patients in our sample (50%) did not receive any thromboprophylaxis; 29 (5.8%) of them were not eligible as they were in the low-risk category; the other 219 patients (44.2%) were divided into two groups. The first group had no obvious reason for not receiving prophylaxis (34.1%) despite their need for it, which could be a result of poor documentation, history taking, or ignorance of the guidelines. While the second group had true contraindications (10.1%); vaginal bleeding was the main contraindication in the OB/GYN ward; and renal impairment in the medical and surgical wards. Other contraindications included: hepatic

impairment, low platelet count, blood disorders, bleeding, active peptic ulcer, intracranial hemorrhage, and use of nonsteroidal anti-inflammatory drugs (NSAIDs). However, in a multinational study by Cohen *et al.*, bleeding at the time of admission was the most common contraindication to thromboprophylaxis, followed by hepatic impairment in medical patients, while in surgical patients; intracranial hemorrhage was the most common<sup>[7]</sup>.

Finally, we noticed that the OB/GYN ward had the least percentage (4.5%) in delivering inappropriate anticoagulant doses compared to the medical and surgical wards. This goes in agreement with the recommendations and guidelines, considering that pregnant women are at higher risk (5-10-fold) of having VTE than non-pregnant women of the same age<sup>[13]</sup>. The Medical ward showed 11% for administering inappropriate doses, while the surgical ward showed 6.1%. A study by Cohen *et al.* showed that out of 17,732 patients at risk for VTE who received the ACCP-recommended prophylaxis, 58.5% were surgical patients and 39.5% were medical<sup>[7]</sup>. This could be explained by the fact that surgical procedures are well known as one of the major risk factors for VTE, and that it has been established for decades that VTE prophylaxis improves outcome in surgical patients<sup>[7, 14, 15, 16, 17]</sup>. With regard to the limitations of this study, the major limitation was incomplete documentations involving bad organization, especially in clarifying past medical and surgical histories. For the future, a multicenter study is much needed to provide greater insight on the adequacy of prophylactic anticoagulant use.

## Conclusion

This cross-sectional study showed proper application of VTE prophylaxis in half of the inpatients. Although there is a degree of compliance to practice guidelines, improvement plans should be considered. There is a slight defect in dealing with at-risk patients. Mechanical prophylaxis can be considered more in patients with contraindications for anticoagulation. Also, we recommend formation of an integrated team to check for VTE at-risk patients; consisting of physicians, pharmacists, and nurses; in order to improve prophylaxis strategies. Finally, continuous medical education in the hospital is critical as VTE prophylaxis adequacy is subject to change and provides continuous opportunity for enhancement by proper planning and application.

## Acknowledgments

We would like to thank the following data collectors in contributing in this research; Badreyah Al-Dauig, Bashaer Basunaid, Bushra AlGhamdi, Eithar Meftah, Haifa Idrees, Hamza Owaidah, Manal Alrogi, Raghadah Khadwardi, Rasha Alharbi, and Renad Ateeq.

## Declaration of conflicting interests

There are no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

## Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

## References

1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis*. 2016; 41(1):3-14. doi: 10.1007/s11239-015-1311-6. PubMed PMID: 26780736; PubMed Central PMCID: PMC4715842.
2. Cushman M. Epidemiology and risk factors for venous thrombosis. *Semin Hematol*. 2007; 44(2):62-9. doi: 10.1053/j.seminhematol.2007.02.004. PubMed PMID: 17433897; PubMed Central PMCID: PMC2020806.
3. Al-Hameed FM, Al-Dorzi HM, Al-Momen AM, Algahtani FH, Al-Zahrani HA, Al-Saleh KA, *et al*. The Saudi Clinical Practice Guideline for the treatment of venous thromboembolism. Outpatient versus inpatient management. *Saudi Med J*. 2015; 36(8):1004-10. doi: 10.15537/smj.2015.8.12024. PubMed PMID: 26219456; PubMed Central PMCID: PMC4549580.
4. Gharaibeh L, Albsoul-Younes A, Younes N. Evaluation of VTE Prophylaxis in an Educational Hospital: Comparison Between the Institutional Guideline (Caprini) and the ACCP Guideline (Ninth Edition). *Clin Appl Thromb Hemost*. 2016; 22(7):627-32. Epub 2015/03/09. doi: 10.1177/1076029615575344. PubMed PMID: 25753966.
5. Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA, Caprini JA. A validation study of a retrospective venous thromboembolism risk scoring method. *Ann Surg*. 2010; 251(2):344-50. doi: 10.1097/SLA.0b013e3181b7fca6. PubMed PMID: 19779324.
6. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. *Ann Intern Med*. 2007; 146(4):278-88. PubMed PMID: 17310052.
7. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, *et al*. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. *Lancet*. 2008; 371(9610):387-94. doi: 10.1016/S0140-6736(08)60202-0. PubMed PMID: 18242412.
8. Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA. Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients. *Am J Med*. 2016; 129(5):528-35. Epub 2015/11/06. doi: 10.1016/j.amjmed.2015.10.027. PubMed PMID: 26551977; PubMed Central PMCID: PMC45331485.
9. Gharaibeh L, Sartawi H, Ayyad D, Juma T, Albassoumi K, Ismail E. Evaluation of venous thromboembolism prophylaxis in a major hospital in a developing country. *Int J Clin Pharm*. 2017; 39(4):881-7. Epub 2017/06/16. doi: 10.1007/s11096-017-0494-7. PubMed PMID: 28623568.
10. Zeitoun AA, Dimassi HI, El Kary DY, Akel MG. An evaluation of practice pattern for venous thromboembolism prevention in Lebanese hospitals. *J Thromb Thrombolysis*. 2009; 28(2):192-9. Epub 2008/12/27. doi: 10.1007/s11239-008-0298-7. PubMed PMID: 19110614.
11. Chandrakumar A, Sajid AM, Suriyaprakash TN, Ajmal KK. Prevalence of venous thromboembolism risk factors and prophylactic adequacy among general surgical patients in a tertiary care hospital. *Indian Heart J*. 2016; 68(4):513-8. Epub 2016/01/12. doi: 10.1016/j.ihj.2015.12.003. PubMed PMID: 27543474; PubMed Central PMCID: PMC4990734.
12. Asano H, Matsubara M, Suzuki K, Morita S, Shinomiya K. Prevention of pulmonary embolism by a foot sole pump. *J Bone Joint Surg Br*. 2001; 83(8):1130-2. PubMed PMID: 11764425.
13. Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. *J Thromb Thrombolysis*. 2016; 41(1):92-128. doi: 10.1007/s11239-015-1309-0. PubMed PMID: 26780741; PubMed Central PMCID: PMC4715853.
14. Baglin T, Barrowcliffe TW, Cohen A, Greaves M, Haematology BCfSi. Guidelines on the use and monitoring of heparin. *Br J Haematol*. 2006; 133(1):19-34. doi: 10.1111/j.1365-2141.2005.05953.x. PubMed PMID: 16512825.
15. Laryea J, Champagne B. Venous thromboembolism prophylaxis. *Clin Colon Rectal Surg*. 2013; 26(3):153-9. doi: 10.1055/s-0033-1351130. PubMed PMID: 24436666; PubMed Central PMCID: PMC3747284.
16. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, *et al*. Prevention of venous thromboembolism. *Chest*. 2001; 119(1Suppl):132S-75S. PubMed PMID: 11157647.
17. Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. *Arch Surg*. 1992; 127(3):310-3. PubMed PMID: 1550477.